Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15716111 | 0.92 | NTRK1 (0.44) | NTRK1 | |
| SCHEMBL15727521 | 0.85 | NTRK1 (0.41) | NTRK1 | |
| SCHEMBL29794762 | 0.84 | MEN1 (0.52) | NTRK1 | |
| SCHEMBL21164880 | 0.83 | NTRK1 (0.56) | NTRK1 | |
| SCHEMBL20217900 | 0.81 | NTRK1 (0.35) | NTRK1 | |
| SCHEMBL15716129 | 0.80 | RAB9A (0.43) | KDM4E | |
| SCHEMBL18093563 | 0.80 | KCNJ6 (0.51) | NTRK1 | |
| SCHEMBL22415930 | 0.80 | NR3C2 (0.47) | NTRK1 | |
| SCHEMBL23505405 | 0.79 | NTRK1 (0.44) | NTRK1 | |
| SCHEMBL21147734 | 0.78 | NTRK1 (0.55) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | TK1, UACA, TDP1 | NTRK1 79/4885KDM4E 2186/4885 |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | NTRK1 79/4885KDM4E 2186/4885 |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | NTRK1 79/4885KDM4E 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.